Gynecologic Cancers | Oncology Today with Dr Neil Love: Key Presentations on Gynecologic Cancers from the 2021 ASCO Annual Meeting

published 2 weeks ago by Dr Neil Love

Featuring an interview with Dr Kathleen Moore, including the following topics: Optimal treatment duration of bevacizumab in combination with paclitaxel/carboplatin for advanced ovarian cancer (0:00) Phase III PAOLA-1 trial subgroup analysis: Progression-free survival outcomes by disease stage in patients with newly diagnosed, homologous recombination-deficient advanced ovarian cancer (4:44) Efficacy and safety results from the randomized Phase II NEOPEMBROV study assessing neoadjuvant chemotherapy with or without pembrolizumab for patients with advanced high-grade serous carcinoma not eligible for front-line debulking surgery (6:50) Combined analysis of Phase III studies assessing the efficacy and safety of niraparib in patients with ovarian cancer with BRCA mutations (11:28) Rucaparib versus chemotherapy for relapsed ovarian carcinoma with BRCA mutation in the platinum-sensitive subgroup of patients: Results from the Phase III ARIEL4 study (13:45) Clinical activity of olaparib combinations in patients with recurrent PARP inhibitor-resistant cancer: Results from the Phase II CAPRI and EFFORT trials (17:55) Efficacy of the combination of mirvetuximab soravtansine and bevacizumab for platinum-agnostic ovarian cancer (25:34) Results from the Phase III OUTBACK trial comparing adjuvant chemotherapy after chemoradiation therapy to chemoradiation therapy alone for locally advanced cervical cancer (27:55) Clinical data with immunotherapeutic agents for cervical cancer; ongoing Phase III innovaTV 301 study assessing tisotumab vedotin versus chemotherapy for recurrent metastatic cervical cancer (31:14) Role of surveillance in the management of endometrial cancer: Results from the TOTEM study (34:51) Antitumor activity of dostarlimab alone or in combination with a PARP inhibitor for recurrent endometrial carcinoma (36:51) Comparison of health-related quality of life with lenvatinib/pembrolizumab versus chemotherapy for patients with advanced endometrial cancer (39:48) Biomarkers of response to immune checkpoint inhibitors; Results from the TAPUR study of dual HER2-targeted therapy for patients with uterine cancer and ERBB2 or ERBB3 abnormalities (41:17) CME information and select publications

more episodes from Research To Practice | Oncology Videos